| Name | Title | Contact Details |
|---|
Lybradyn Inc is a Oak Brook, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Madeira Therapeutics is a Overland Park, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Left unchecked, two base rats, a male and a female, can result in 15,000 descendants in about 12 months. It`s easy to see how quickly this can lead to infestations and even population rebounds if just two rats are left behind after a knockdown program. That`s where we come in. We`re SenesTech, the rat fertility experts and the makers of ContraPest®, the first and only EPA-registered rat fertility restrictor impacting both male and female rats. We make it possible to target both ends of the lifecycle—birth and death—by adding fertility control to your integrated pest management (IPM) solution. Controlling the birth rate with ContraPest will magnify the success of your existing IPM protocols. ContraPest is the one-of-a-kind, innovative technology that targets the reproductive capabilities of both male and female Norway and roof rats. Sweet and fatty, it`s highly palatable like a “milkshake” rats can`t get enough of. By using ContraPest, you can reduce the rat population and keep it down because ContraPest works!
Ionpath delivers high definition spatial proteomics, revolutionizing tissue imaging and analysis to accelerate discovery and improve human health. Ionpath`s MIBI™ (multiplexed ion beam imaging) Platform breaks through the limitations of traditional IHC, enabling deep understanding of the tissue microenvironment with highly multiplexed quantitative single-cell analysis.
Vital Therapies, Inc. is a biotherapeutic company focused on developing a cell-based system for the treatment of acute liver failure. Our product candidate, the ELAD® System, is a human cell-based, bio-artificial liver support system that operates outside the body, or extracorporeally, and is designed with the proposed intent to allow the patient’s own liver to regenerate to a healthy state, or to stabilize the patient until liver transplant. The ELAD System incorporates our human liver-derived cells, or VTL C3A cells, contained in four hollow fiber cartridges, that are combined with single use customized disposable sets and an ancillary delivery system. Data from ELAD clinical studies has shown trends that may indicate a potential to increase survival rates in patients with acute liver failure. ELAD has received orphan designation in the United States and Europe for the treatment of acute liver failure. Prior to the initiation of our ongoing Phase III clinical trial program, over 145 subjects have received therapy with the ELAD System in seven clinical trials and through a compassionate use program, which we believe collectively suggests a promising therapeutic profile. In March 2013, we initiated VTI-208, a Phase III randomized, controlled clinical trial in 200 subjects with alcohol-induced liver decompensation. We reached the midpoint in enrollment of this trial in April 2014, and anticipate the release of preliminary data in the first half of 2015. In addition, we are conducting a second Phase III randomized, controlled clinical trial, VTI-210, in 150 subjects with severe acute alcoholic hepatitis, or AAH, which is a subset of AILD, and expect to initiate enrollment of subjects later in 2014. In the second quarter of 2014, we began enrollment of a Phase II clinical trial of the ELAD System in subjects with either fulminant hepatic failure, or FHF, or surgery-induced acute liver failure, or SILF. We anticipate the release of data from VTI-210 in 2016 and the Phase II component of VTI-212 in 2015 or 2016.